Kamal Girgis, MD
Internal Medicine · Bedford, INNPI 1659365484
Payments from drug & device makers
Across 6 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$46
- Inari Medical, Inc.$33
- Alkermes, Inc.$16
- Boston Scientific$15
- Exact Sciences$15
What the payments were for
- Food & beverage$7963%
- Education$4637%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $46 |
| Inari Medical, Inc. | 1 | $33 |
| Alkermes, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Exact Sciences | 1 | $15 |
How this compares
$125 in reported general payments places this provider in the 40th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 175 | $228,910 |
| EliquisApixaban | 182 | $175,446 |
| OzempicSemaglutide | 103 | $138,990 |
| TrulicityDulaglutide | 79 | $116,664 |
| JardianceEmpagliflozin | 79 | $73,220 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $70,670 |
| JanuviaSitagliptin Phosphate | 50 | $47,867 |
| LinzessLinaclotide | 45 | $39,124 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $27,987 |
| XareltoRivaroxaban | 27 | $26,640 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 582 | $16,457 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $15,802 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 118 | $15,264 |
| MyrbetriqMirabegron | 26 | $14,715 |
| FarxigaDapagliflozin Propanediol | 17 | $14,203 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bedford
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.